PETALUMA, Calif., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced it will host its 2012 New York City Financial Analysts Presentation on November 5, 2012 from 11:30 am-1:00 pm ET. Moderated by Suraj Kalia, senior vice president of Northland Capital Markets, the presentation will include a panel discussion by medical experts of the current use of the Microcyn® Technology platform in both post-surgical settings and in the treatment of skin dermatoses, including atopic dermatitis. They will also share their perspectives on the potential impact of the Microcyn Technology in both the surgical and acne markets once respective regulatory drug approvals are secured for those indications.
Addressing post-surgical use of the technology are Robert Fridman, DPM, AALFAS, a member of New York Presbyterian Columbian University Medical Center, and Tom Wolvos, MD, FACS, of Scottsdale Surgical Consultants in Arizona. Rebecca Smith, MD, pediatric dermatologist at Fort Mill Dermatology in South Carolina and Firas George Hougeir, MD, FAAD, a board-certified dermatologist in Atlanta, Georgia will review Microcyn Technology use in dermatology.
Attendance at the event is by invitation only. However, interested parties may listen to the live audio via telephone or the internet.
Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 38939267. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.
About Oculus Innovative Sciences
Oculus Innovative Sciences is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "share," "impact" and "secured," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.
Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.